Valuation: Indivior

Market Cap 494.09Cr 434.75Cr 404.02Cr 370.97Cr 696.27Cr 48TCr 707.97Cr 4.8TCr 1.87TCr 23TCr 1.85TCr 1.81TCr 81TCr P/E 2026 *
12.8x
P/E 2027 * 11.2x
Enterprise Value 499.54Cr 439.54Cr 408.47Cr 375.06Cr 703.95Cr 48TCr 715.77Cr 4.85TCr 1.89TCr 24TCr 1.88TCr 1.83TCr 82TCr EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.46x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 494.09Cr
+0.86%+1.43%+48.50%+160.39% 1,06700Cr
+1.59%+4.09%+55.34%+53.96% 63TCr
+0.95%+1.91%+35.91%+81.14% 46TCr
+1.60%+6.25%+33.95%+29.84% 35TCr
-0.60%+1.52%+35.68%+39.76% 30TCr
-0.14%+0.60%+16.17%+17.53% 26TCr
+0.09%-2.82%-28.29%-41.71% 22TCr
+1.22%+2.66%+21.87%+59.73% 20TCr
-1.18%-3.70%+14.23%+66.51% 16TCr
Average +0.45%+1.33%+25.93%+51.91% 40.48TCr
Weighted average by Cap. +0.76%+1.95%+35.81%+77.68%

Financials

2026 *2027 *
Net sales 126.01Cr 110.88Cr 103.04Cr 95Cr 177.57Cr 12TCr 180.56Cr 1.22TCr 477.89Cr 5.96TCr 473.02Cr 462.82Cr 21TCr 131.24Cr 115.48Cr 107.32Cr 99Cr 184.95Cr 13TCr 188.06Cr 1.27TCr 497.74Cr 6.21TCr 492.66Cr 482.05Cr 21TCr
Net income 41Cr 36Cr 34Cr 31Cr 58Cr 4TCr 59Cr 402.52Cr 157.19Cr 1.96TCr 155.58Cr 152.23Cr 6.79TCr 47Cr 42Cr 39Cr 36Cr 67Cr 4.57TCr 68Cr 459.23Cr 179.33Cr 2.24TCr 177.5Cr 173.68Cr 7.75TCr
Net Debt 5.45Cr 4.8Cr 4.46Cr 4.09Cr 7.68Cr 526.25Cr 7.81Cr 53Cr 21Cr 257.95Cr 20Cr 20Cr 892.66Cr -40Cr -35Cr -33Cr -30Cr -57Cr -3.9TCr -58Cr -391.77Cr -152.99Cr -1.91TCr -151.43Cr -148.16Cr -6.61TCr
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-